GSK plc
bepirovirsen
chronic hepatitis B
Date
TBD
FDA decision · Date TBD estimated
What's at stake
An FDA complete response letter on bepirovirsen for chronic hepatitis B is in focus around Date TBD.
Primary source
· SEC 6-K
verified 11h ago
“Bepirovirsen demonstrated an acceptable safety and tolerability profile consistent with previous studies.”